And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

Ramesh Kumar Biography and Net Worth

Director of Ocugen

Dr. Ramesh Kumar Ph.D. serves as Independent Director of the Company. Dr. Kumar has served as a director of OpCo, our wholly owned subsidiary, since June 2019. He co-founded Onconova Therapeutics, Inc. in 1998 and served as its Chief Executive Officer and a member of its board from 1998 to February 2019 and as its President from 1998 to June 2018. Dr. Kumar transitioned to an Advisory role with Onconova in January 2019. He has held positions in R&D and management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he served as President of the Genomics and Transgenics Division. Dr. Kumar obtained an undergraduate and Master’s degree in Microbiology from Panjab University and received his Ph.D. in Molecular Biology from the University of Illinois, Chicago and trained at the National Cancer Institute. Our Board believes Dr. Kumar’s extensive senior executive and public company experience, and familiarity with the pharmaceutical industry qualify him to serve on our Board.

What is Ramesh Kumar's net worth?: The estimated net worth of Ramesh Kumar is at least $8,850.00 as of July 19th, 2021. Dr. Kumar owns 7,500 shares of Ocugen stock worth more than $8,850 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Learn More about Ramesh Kumar's net worth.
How do I contact Ramesh Kumar?: The corporate mailing address for Dr. Kumar and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Ramesh Kumar's contact information.
Has Ramesh Kumar been buying or selling shares of Ocugen?: Ramesh Kumar has not been actively trading shares of Ocugen during the last ninety days. Most recently, Ramesh Kumar sold 4,500 shares of the business's stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $1.83, for a transaction totalling $8,235.00. Learn More on Ramesh Kumar's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.
Are insiders buying or selling shares of Ocugen?: In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 200,278 shares worth more than $100,139.00. The most recent insider tranaction occured on June, 14th when Director Junge Zhang bought 200,278 shares worth more than $100,139.00. Insiders at Ocugen own 3.5% of the company. Learn More about insider trades at Ocugen.
Information on this page was last updated on 6/14/2023.

Ramesh Kumar Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2022	Sell	4,500	$1.83	$8,235.00
7/18/2022	Sell	7,500	$2.57	$19,275.00
4/18/2022	Sell	7,500	$2.83	$21,225.00
1/18/2022	Sell	7,500	$4.07	$30,525.00
7/19/2021	Sell	7,500	$6.40	$48,000.00	7,500
4/19/2021	Sell	7,500	$5.33	$39,975.00	7,500

Ramesh Kumar Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $1.18

$1.11

$1.25

50 Day Range

MA: $1.28

$0.79

$1.88

2 Week Range

Now: $1.18

$0.35

$2.11

Volume

6,857,403 shs

Average Volume

8,081,555 shs

Market Capitalization

$303.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.51

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here